Suzuki Kazuhiro, Matsui Hiroshi, Nakazato Haruki, Koike Hidekazu, Okugi Hironobu, Hasumi Masaru, Ohtake Nobuaki, Nakata Seiji, Takei Tomoyuki, Hatori Motoaki, Ito Kazuto, Yamanaka Hidetoshi
Department of Urology, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi-City, Japan.
Cancer Lett. 2003 Jun 10;195(2):177-83. doi: 10.1016/s0304-3835(03)00182-4.
Association between genetic polymorphisms of CYP1A1 and familial prostate cancer risk was examined by a case-control study of 185 individuals. Although the individual analysis of m1 or m2 genotype of CYP1A1 showed no significant association with prostate cancer risk, the presence of any mutated alleles significantly increased prostate cancer risk in comparison with wild-type genotypes by combination analysis (odds ratio [OR]=2.38; 95% confidence interval [CI]=1.72-3.29; P=0.0069). Furthermore, metastatic cancer had a significant association with mutated alleles of m1 and m2. These finding suggested that CYP1A1 polymorphisms has an association with prostate cancer risk, especially with progression of prostate cancer.
通过对185名个体进行病例对照研究,检测了CYP1A1基因多态性与家族性前列腺癌风险之间的关联。虽然对CYP1A1的m1或m2基因型进行的个体分析显示与前列腺癌风险无显著关联,但通过联合分析发现,与野生型基因型相比,任何突变等位基因的存在均显著增加了前列腺癌风险(优势比[OR]=2.38;95%置信区间[CI]=1.72 - 3.29;P=0.0069)。此外,转移性癌症与m1和m2的突变等位基因有显著关联。这些发现表明,CYP1A1基因多态性与前列腺癌风险相关,尤其是与前列腺癌的进展相关。